Brief: Brickell Biotech Announces Initiation Of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel 15% For Treatment Of Primary Axillary Hyperhidrosis
06/10/2020 12:05
Oct 6 (Reuters) - Brickell Biotech Inc BBI.O :
* BRICKELL BIOTECH ANNOUNCES INITIATION OF U.S. PHASE 3
PROGRAM
EVALUATING SOFPIRONIUM BROMIDE GEL, 15% FOR TREATMENT OF PRIMARY
AXILLARY HYPERHIDROSIS
Source text for Eikon: ID:nGNX6hZPr9
Further company coverage: BBI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh Tracks Therapeutics
See all newsBrief: Fresh Tracks Therapeutics Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Fresh Tracks Therapeutics Intends To Seek Judicial Dissolution If Liquidation And Approved By Stockholders
Brief: Fresh Tracks Therapeutics Q3 EPS USD 0.32
Brief: Fresh Tracks Therapeutics Inc On October 10 Received A Notice From Listing Qualifications Department Of Nasdaq
U.S. STOCKS ON THE MOVE-Gold miners, Goosehead Insurance, FedEx